Pfizer's proposed acquisition of biopharmaceutical company Medivation is aimed at making them a leader in the oncology space while working to bring two of Medivation's most promising late-stage assets to patients.
Specialty Pharmacy News
The New York Times is reporting that the market for osteoporosis drugs might be getting a shakeup soon, as a competitor to Forteo, Eli Lilly & Co.'s osteoporosis treatment, completes a large clinical trial. The new drug uses a hormone that can build bone growth, and its maker, Radius, has an application pending before the Food and Drug Administration that the report says is expected to be approved. (New York Times)
Zinbryta is generally reserved for patients with inadequate responses to two or more multiple sclerosis therapies.
CareTrend allows users to manage their entire workflow operations from a single dashboard that can track output and identify delays while tracking employee productivity in real time.
Diplomat Pharmacy on Tuesday announced the results of its second quarter, reporting total revenue of $1.09 billion, a 35% increase over the same quarter in 2015.
USA Today is reporting that CVS Health has announced plans to remove two biologic drugs, Neupogen and Lantus, from its pharmacy benefits manager (PBM) formulary in 2017 and replace them with biosimilars of the drugs, substituting Zarxio for Neupogen and Basaglar for Lantus. Biosimilars cost about 15% to 30% less than the original biologics. CVS’s EVP and chief medical officer Troyen Brennan told USA Today that the biologics were reviewed by panels of experts “to make sure they are considered equivalent. (USA Today)
DSN associate editor David Salazar examines chain pharmacy, including in-depth coverage of pharmacy spending, telehealth, generics and technology, in this multi-page report.
For the second year in a row, spending on medicines in 2015 grew by double-digits, increasing 12.2% on an invoice basis to $424.8 billion, according to the IMS Institute for Healthcare Informatics’ medicine report on spending for 2015.
Among the biosimilars researchers focused on was Inflectra, which was developed by Pfizer’s Hospira as a biosimilar to Janssen Biotech’s Remicade.